Sarah Gheuens - Dec 2, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol: AGIO
Transactions as of: Dec 2, 2022
Transactions value $: -$7,150
Form type: 4
Date filed: 12/6/2022, 03:14 PM
Previous filing: Mar 3, 2022
Next filing: Dec 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+833	+9.88%	$0.00	9.26K	Dec 2, 2022	Direct	F1
transaction	AGIO	Common stock	Tax liability	-$7.15K	-248	-2.68%	$28.83	9.01K	Dec 6, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-833	-100%	$0.00^*	0	Dec 2, 2022	Common stock	833		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 660 shares purchased through the Company's employee stock purchase plan.
F2	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3	The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.